EASD Abstract SIDS 28032019.docx (278.75 kB)
The metabolic effects of an SGLT2 inhibitor (dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes
conference contribution
posted on 2020-05-13, 13:32 authored by R Herring, F Shojaee-Moradie, R Garesse, M Stevenage, N Jackson, C Lucy, BA Fielding, A Umpleby, DL Russell-Jones, M DaviesThe metabolic effects of an SGLT2 inhibitor (dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes